Table 4. SVR rates in genotype 1-infected patients treated with PegIFN/RBV +/- BOC or TVR
Back to Tables
| Study cohort, N | SVR to PI/PegIFN/RBV (arm 1 of trial) | SVR to PI/PegIFN/RBV (arm 2 of trial) | SVR with PegIFN/RBV |
|---|
| BOC, boceprevir; eRVR, extended rapid virologic response; HCV, hepatitis C virus; PegIFN, peginterferon alfa; PI, protease inhibitor; RBV, ribavirin; RGT, response-guided therapy; SVR, sustained virologic response; TVR, telaprevir. |
| Treatment-naive |
|---|
| BOC (SPRINT-2), SVR%
| 63
| 66
| 38
|
| N = 1,099 (11)
| BOC/PegIFN/RBV RGT
| BOC/PegIFN/RBV 44 weeks
| PegIFN/RBV 48 weeks |
| TVR (ADVANCE), SVR%
| 69
| 75
| 44
|
| N = 1,088 (12)
| TVR for 8 weeks/PegIFN/RBV RGT
| TVR for 12 weeks/PegIFN/RBV RGT
| PegIFN/RBV 48 weeks
|
| TVR (ILLUMINATE), SVR%
| 71
| 73
| NA
|
| N = 540 (49)
| TVR for 12 weeks/PegIFN/RBV (24 total weeks) if eRVR
| TVR for 12 weeks/PegIFN/RBV(48 total weeks) if eRVR
| -
|
| Treatment-experienced |
|---|
| TVR (REALIZE), SVR% overall
| -
| -
| |
| N = 662 (13)
| NA
| 64-66
| 17
|
| TVR for 12 weeks/PegIFN/RBV (48 weeks total)
| | | |
| Prior relapsers (SVR%)
| -
| 83-88
| 24
|
| Prior partial responders (SVR%)
| -
| 54-59
| 15
|
| Prior null responders (SVR%)
| -
| 29-33
| 5
|
| BOC (RESPOND-2), SVR% overall
| | | |
| N = 403 (14)
| 59
| 66
| 21
|
| BOC/PegIFN/RBV (48 weeks total)
| | | |
| Prior relapsers (SVR%)
| 69
| 75
| 29
|
| Prior partial responders (SVR%)
| 40
| 52
| 7
|
